These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20006497)

  • 1. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors-Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity.
    Lin H; Yamashita DS; Zeng J; Xie R; Wang W; Nidarmarthy S; Luengo JI; Rhodes N; Knick VB; Choudhry AE; Lai Z; Minthorn EA; Strum SL; Wood ER; Elkins PA; Concha NO; Heerding DA
    Bioorg Med Chem Lett; 2010 Jan; 20(2):673-8. PubMed ID: 20006497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
    Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
    J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
    Zhu GD; Gong J; Gandhi VB; Woods K; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Stoll VS; Mamo M; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem; 2007 Mar; 15(6):2441-52. PubMed ID: 17258463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
    Hu Z; Wang C; Sitkoff D; Cheadle NL; Xu S; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127474. PubMed ID: 32805407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles.
    Lin H; Yamashita DS; Zeng J; Xie R; Verma S; Luengo JI; Rhodes N; Zhang S; Robell KA; Choudhry AE; Lai Z; Kumar R; Minthorn EA; Brown KK; Heerding DA
    Bioorg Med Chem Lett; 2010 Jan; 20(2):679-83. PubMed ID: 20005102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors.
    Woods KW; Fischer JP; Claiborne A; Li T; Thomas SA; Zhu GD; Diebold RB; Liu X; Shi Y; Klinghofer V; Han EK; Guan R; Magnone SR; Johnson EF; Bouska JJ; Olson AM; de Jong R; Oltersdorf T; Luo Y; Rosenberg SH; Giranda VL; Li Q
    Bioorg Med Chem; 2006 Oct; 14(20):6832-46. PubMed ID: 16843670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA.
    Xu R; Banka A; Blake JF; Mitchell IS; Wallace EM; Bencsik JR; Kallan NC; Spencer KL; Gloor SL; Martinson M; Risom T; Gross SD; Morales TH; Wu WI; Vigers GP; Brandhuber BJ; Skelton NJ
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2335-40. PubMed ID: 21420856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
    Li Q; Woods KW; Thomas S; Zhu GD; Packard G; Fisher J; Li T; Gong J; Dinges J; Song X; Abrams J; Luo Y; Johnson EF; Shi Y; Liu X; Klinghofer V; Des Jong R; Oltersdorf T; Stoll VS; Jakob CG; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2000-7. PubMed ID: 16413780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors.
    Seefeld MA; Rouse MB; McNulty KC; Sun L; Wang J; Yamashita DS; Luengo JI; Zhang S; Minthorn EA; Concha NO; Heerding DA
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2244-8. PubMed ID: 19285393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and SAR of spirochromane Akt inhibitors.
    Kallan NC; Spencer KL; Blake JF; Xu R; Heizer J; Bencsik JR; Mitchell IS; Gloor SL; Martinson M; Risom T; Gross SD; Morales TH; Wu WI; Vigers GP; Brandhuber BJ; Skelton NJ
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2410-4. PubMed ID: 21392984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
    Zhu GD; Gong J; Claiborne A; Woods KW; Gandhi VB; Thomas S; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Stoll VS; De Jong R; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3150-5. PubMed ID: 16603355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
    Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
    Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
    Hartnett JC; Barnett SF; Bilodeau MT; Defeo-Jones D; Hartman GD; Huber HE; Jones RE; Kral AM; Robinson RG; Wu Z
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2194-7. PubMed ID: 18294842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.
    Zhu GD; Gandhi VB; Gong J; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Jarvis K; Park C; Jong RD; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3424-9. PubMed ID: 16644221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imidazo[1,2-a]pyridine-based peptidomimetics as inhibitors of Akt.
    Kim YB; Kang CW; Ranatunga S; Yang H; Sebti SM; Del Valle JR
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4650-4653. PubMed ID: 25205195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
    Kendall JD; Giddens AC; Tsang KY; Frédérick R; Marshall ES; Singh R; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
    Bioorg Med Chem; 2012 Jan; 20(1):58-68. PubMed ID: 22177407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel ROCK1 Inhibitors via Integrated Virtual Screening Strategy and Bioassays.
    Shen M; Tian S; Pan P; Sun H; Li D; Li Y; Zhou H; Li C; Lee SM; Hou T
    Sci Rep; 2015 Nov; 5():16749. PubMed ID: 26568382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.
    Lin H; Yamashita DS; Xie R; Zeng J; Wang W; Leber J; Safonov IG; Verma S; Li M; Lafrance L; Venslavsky J; Takata D; Luengo JI; Kahana JA; Zhang S; Robell KA; Levy D; Kumar R; Choudhry AE; Schaber M; Lai Z; Brown BS; Donovan BT; Minthorn EA; Brown KK; Heerding DA
    Bioorg Med Chem Lett; 2010 Jan; 20(2):684-8. PubMed ID: 20006500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
    Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
    Sehon CA; Wang GZ; Viet AQ; Goodman KB; Dowdell SE; Elkins PA; Semus SF; Evans C; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
    J Med Chem; 2008 Nov; 51(21):6631-4. PubMed ID: 18842034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.